Evidence map›Paper›PMID 37542624›Full record

ReviewNeurology and therapy2023

Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review.

Andrew M Blumenfeld, Richard B Lipton, Stephen Silberstein, Stewart J Tepper, Larry Charleston, Stephen Landy, Deena E Kuruvilla, Aubrey Manack Adams

Open access · goldAbstract readReview
In one paragraph

Review in Neurology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Integrating manual therapy into headache management: bridging the evidence gap.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Andrew M BlumenfeldThe Los Angeles and San Diego Headache Centers, San Diego, CA, USA. ablumenfeldmd@gmail.com.ORCID http://orcid.org/0000-0003-0851-4914
Richard B LiptonAlbert Einstein College of Medicine, Bronx, NY, USA.
Stephen SilbersteinDepartment of Neurology, Thomas Jefferson University, Philadelphia, PA, USA.
Stewart J TepperNew England Institute for Neurology and Headache, Stamford, CT, USA.
Larry CharlestonDepartment of Neurology and Ophthalmology, Michigan State University College of Human Medicine, East Lansing, MI, USA.ORCID http://orcid.org/0000-0002-7708-5394
Stephen LandyTupelo Headache Clinic, Tupelo, MS, USA.ORCID http://orcid.org/0000-0003-0553-1305
Deena E KuruvillaWestport Headache Institute, Westport, CT, USA.ORCID http://orcid.org/0000-0002-1997-5663
Aubrey Manack AdamsAbbVie, Irvine, CA, USA.
AbbVie (United States) · USAlbert Einstein College of Medicine · USFamily Health Centers of San Diego · USMichigan State University · USNew England Institute for Neurology and Headache · USThomas Jefferson University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Migraine is a neurologic disease with a complex pathophysiology that can be controlled with current treatment options but not cured. Therefore, treatment expectations are highly variable. The concept of migraine freedom was recently introduced and can mean different things, with some, for example, expecting complete freedom from headache and associated symptoms and others accepting the occasional migraine attack if it does not impact functioning. Therefore, migraine management should be optimized so that patients can have the best opportunity to achieve their optimal treatment goals. With migraine freedom as a goal and, given the complex pathophysiology of migraine and the high incidence of comorbidities among individuals with migraine, treatment with a single modality may be insufficient, as it may not achieve migraine freedom in those with more frequent or disabling attacks. In this clinical perspective article, we have identified four key, partially overlapping principles of multimodal migraine treatment: (1) manage common comorbidities; (2) control modifiable risk factors for progression by addressing medication and caffeine overuse; (3) diagnose and treat secondary causes of headache, if present; and (4) individualize acute and preventive treatments to minimize pain, functional disability, and allodynia. There are many barriers to pursuing migraine freedom, and strategies to overcome them should be optimized. Migraine freedom should be an aspirational goal both at the individual attack level and for the disease overall. We believe that a comprehensive and multimodal approach that addresses all barriers people with migraine face could move patients closer to migraine freedom.

Indexed as

Drug targetingExpert opinionsMigraine disordersMultimodal treatment

Identifiers

PMID37542624
PMCPMC10444724
OpenAlexW4385597016

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.